The French pharmaceutical firm Sanofi is selling its flagship paracetamol-based product 'Doliprane' to a US fund, prompting a backlash: "We're not at all reassured by the fact that this drug, which is France's flagship product, is being sold to foreign investors," says Corinne Feret, a Socialist senator from Calvados. Trade union leaders and some politicians are concerned following the announcement of the sale of the Opella subsidiary, which produces Doliprane in particular, to an American pension fund. IMAGES AND SOUNDBITES